摘要
目的观察重组人血管内皮抑素联合DIA方案治疗骨肉瘤的临床效果。方法将我院2007年9月至2008年9月收治的76例骨肉瘤患者随机分成观察组和对照组,每组38例。所有患者手术治疗后,观察组采用重组人血管内皮抑素联合DIA方案治疗,对照组采用DIA方案治疗,比较两组的临床疗效、不良反应、5年生存曲线以及肢体功能。结果观察组和对照组的临床有效率分别为71.0%、51.3%,观察组显著高于对照组,差异有统计学意义(P<0.05);两组患者不良反应的差异无统计学意义(P>0.05);而5年生存曲线以及肢体功能的差异有统计学意义(P<0.05)。结论重组人血管内皮抑素联合DIA方案治疗骨肉瘤的疗效较单用DIA方案更好,且安全性高,值得在临床推广。
Objective To explore the clinical effects of recombinant human endostatin combined with DIA on osteosarcoma. Methods Between Sept. 2007 and Sept. 2008, 76 patients with osteosarcoma admitted in our hospital were randomly divided into the observation group and the control group （38 cases in each）. After surgery, the observation group was treated with recombinant human endostatin combined with DIA, while the control group was treated with DIA. The clinical effects, side effects, 5-year survival curve and limb function were compared between the two groups. Results The total clinical effective rate of the observa.- tion group （71.0%） was significantly higher than that of the control group （51.3%） （P〈0.05）. No statistical difference was found in the side effects between the two groups （P〉0.05）. The 5-year survival curve and limb function of the observation group were significantly superior to those of the control group （P〈0.05）. Conclusion The recombinant human endostatin combined with DIA had better clinical effects on osteosarcoma than DIA alone. It also had high safety and was worth popularizing.
出处
《肿瘤药学》
CAS
2013年第5期368-371,共4页
Anti-Tumor Pharmacy
